



## VERIFICATION

I, Dr. STEFAN MÜLLER-BECKER, Dipl.-Chemiker,  
technical translator of the firm of

VON KREISLER SELTING WERNER *et al.*, Patent Attorneys,  
Deichmannhaus am Dom, D-50667 Cologne,

do hereby solemnly and sincerely declare:

THAT I am fully familiar with the German and  
English languages,

THAT I am a competent translator thereof,

THAT to the best of my knowledge and belief the  
following is a true and correct translation made by me  
of the document in the German language attached hereto  
and identified as the Certificate dated  
February 20, 2001, and Reproduction of the  
Original Document of the Patent Application filed on  
December 30, 1999, with the German Patent and Trade  
Mark Office (File No. 199 64 046.7).

Signed this twenty-fifth day of May 2004

Stefan Müller-Becker

Translation

Federal Republic of Germany

[German Coat of Arms]

**Priority certificate on the filing of a patent application**

**File number:** 199 64 046.7  
**Date of application:** December 30, 1999  
**Applicant/Patentee:** Dr. med. Hans-Georg Frank, Aachen/DE  
**Title:** Method for the Identification of Substances  
Mimicking Mammal Epitopes  
**IPC:** A 61 K, C 07 K, C 12 N

**The attached document is a correct and exact copy of the original document of this Patent Application.**

Munich, February 20, 2001

**German Patent and Trade Mark Office**

**The President**

Per pro

*(Signature)*

### Method for the Identification of Substances Mimicking Mammal Epitopes

The present invention relates to a method for the preparation of specific monoclonal immunological binding molecules having binding capacity to mammal epitopes, and the immunological binding molecules, and a method for the identification of low molecular weight substances mimicking mammal epitopes, and the corresponding low molecular weight substances.

Methods for the preparation of immunological binding molecules, especially antibodies, are known to those skilled in the art. Common methods are based on the immunization of host animals with substances against which antibodies are to be raised. To enhance the immune response, adjuvants containing highly potent immunogens are usually added. The immune response achieved in the host animal by one or more immunizations can be used in the form of polyclonal antibody sera or immortalized by hybridoma technology, optionally followed by monoclonalization through isolation of single cells.

Alternatively, the genetic information contained in the cells relating to the structure of antibodies can be used to obtain synthetic binding molecules, such as single-chain antibodies.

All these methods rely on the original immunization of the host animal and therefore depend on the quality of the immune response produced thereby. It is to be taken into account that the animals used for immunization when immortalization of the immune response using hybridoma technology is intended are almost exclusively mice since appropriate immortalized myeloma cells are available only for laboratory rodents.

In the usual immunization of mice or rabbits, good immune responses are achieved only when the corresponding protein is recognized as "foreign" by the host animal. This is a problem, in particular, when the relevant structures are structures which were conserved over a long stretch of evolution.

In many cases, it is of particular interest to establish also the structures of the substances acting as immunogens. For example, when they are simple peptides and proteins, they can be identified by means of the immunological binding molecules obtained and isolated and characterized by chromatographical methods. The exact structural elucidation is subsequently effected, for example, by protein sequencing.

However, when the immunogenic structures are compounds having a complex structure, e.g., because lipid structures are involved, characterization is more difficult because compounds like these often lose their structure when purified and thus are no longer recognized by the immunological binding molecules. In such a case, substances having identical three-dimensional structures would be of great interest since such substances could possibly be used as components of vaccines to achieve immunization.

It has been the object of the present invention to overcome the mentioned problems and drawbacks of the prior art.

In one aspect of the invention, the object is achieved by a method for the preparation of specific monoclonal immunological binding molecules having binding capacity to mammal epitopes, comprising the following steps:

- a) isolation of structures containing said epitopes to obtain an epitope preparation;
- b) immunization of non-mammals with the epitope preparation to obtain an immune response;

- c) immortalization of the immune response to obtain a library of immunological binding molecules;
- d) selection of the immunological binding molecules by means of the epitopes to obtain specific monoclonal immunological binding molecules.

An "immunological binding molecule" as used herein means a molecule which is directly or indirectly obtained by immunization and can bind to other molecules. In particular, the term encompasses antibodies and antibody fragments as well as single-chain antibodies.

"Specific immunological binding molecules" means that these binding molecules will bind to other substances with a dissociation constant,  $K_d$ , of less than  $10^{-5}$ , preferably between  $10^{-6}$  and  $10^{-12}$ , mol/l.

"Monoclonal immunological binding molecules" are those which can be produced by a plurality of cells, but wherein all cells express identical binding molecules.

"Immortalization of the immune response" means that the immune response obtained is converted to a form which allows to have corresponding binding molecules produced by cells in vitro over an extended period of time.

A "library of immunological binding molecules" means a plurality of different binding molecules which are still connected to their DNA information in such a way that monoclonal binding molecules can be obtained by isolating single members of the library.

"Selection of immunological binding molecules" means a method by which the binding capacity of the binding molecules to substances is tested, and molecules exhibiting high binding affinities are isolated.

The method is useful, in particular, for conserved epitopes. "Conserved epitopes" of mammals are especially those which

- a) occur in different mammal species; and

- b) have relatively few interspecies differences; and optionally
- c) are characterized in that consensus sequences or consensus structures can be defined at least for the mammals, c) applying only for epitopes of which sequence data can be established due to their type of material.

Conserved mammal epitopes have a higher immunogenicity in non-mammals than they have in mammals.

Herein, the term "conserved epitopes" is intended to encompass, in addition to this meaning derived from phylogenesis, also all ontogenetically relevant human epitopes which

- a) are expressed in human trophoblastic tissue, in human embryonic tissue, and/or in malignant degenerate cells and tissues or intermediate stages between normal and malignant degenerate tissue; and
- b) are not expressed in the normal adult cells and tissues which are differentiated in a way typical of that tissue and which correspond to said malignant degenerate cells; and
- c) are characterized by exhibiting, as a rule, a lower immunogenicity in mammals than they exhibit in non-mammals which lack both trophoblast and placenta.

The preferred species for immunization are chickens.

A further aspect of the invention is a method for the identification of low molecular weight substances mimicking mammal epitopes, wherein the specific monoclonal immunological binding molecules obtained by the method mentioned above are used for identifying, in a library of low molecular weight substances, those having a high binding affinity for the immunological binding molecules. Thus, appropriate molecules mimic the native structure of the originally employed epitopes, but can

be selected from basically different classes of substances; they have similar stereochemical properties.

The preferred mammal species the epitopes of which are of interest is *Homo sapiens*.

Said library of low molecular weight substances preferably contains peptides, especially in the form of a phage peptide library. Preferably, the peptides comprise from 7 to 15 amino acids, more preferably 9 or more and 12 or less amino acids.

The invention also relates to the immunological binding molecules which can be obtained by the method according to the invention, a diagnostic agent which contains the immunological binding molecules, a low molecular weight substance which can be identified by the method according to the invention for the identification of the low molecular weight substances, and a medicament containing one of the low molecular weight substances according to the invention.

In a preferred embodiment, the methods according to the invention can be employed for producing a vaccine for contraception.

WO-A-93/06857 already describes a vaccine for contraception in which a protein composition purified from trophoblast membranes is used as a vaccine. Due to the low immunogenicity of human epitopes in humans, little success is to be expected from this.

In humans, the early embryo invasively implants itself as a blastocyst in the stromal portion of the endometrium, i.e., the blastocyst penetrates the uterine epithelium, which results in interstitial implantation. The penetrating cell population is the outer, epithelial stratum of cells, the so-called trophoblast. Interstitial implantation occurs in humans and in a number of related mammals, such as mice and rats. During the whole pregnancy, single trophoblast cells penetrate the maternal tissues to within the region of the endometrial/myometrial transition zone, penetrate the wall of maternal arteries and replace the endothelium there. When penetrating the uterine epithelium, the cells of the trophoblast fuse to a

syncytial aggregate, a process which is indispensable to a successful implantation. The process of trophoblastic syncytiogenesis is triggered by signal epitopes of which it is only known to date that a flip of phosphatidylserine to the exterior of the plasma membrane is involved in their generation. Thus, it is known that

- a) women having an increased anti-phospholipid antibody level (e.g., in lupus erythematoses) have more problems during pregnancy and are in part infertile;
- b) the externalization of phosphatidylserine to the exterior of the plasma membrane immediately precedes the syncytial fusion;
- c) antibodies induced against phosphatidylserine in test animals can inhibit syncytial fusion in vitro.

The flip of phosphatidylserine is not a trophoblast-specific phenomenon, but an event occurring in the body during each apoptosis. Apoptotic cells fuse rarely, and if so, they do it always with similar cells. Therefore, there are postulated further epitopes which may be associated with phosphatidylserine and which trigger the tissue-specific event of syncytial fusion only in trophoblasts, in the genesis of skeletal muscular fibers, and in osteoclasts. Since these epitopes formed with the participation of phosphatidylserine are not pure protein epitopes, they are difficult to isolate and characterize biochemically.

Using the method according to the invention, substances can be isolated which are suitable as vaccines for inhibiting syncytial fusion. Thus, for example, trophoblast preparations may be used to immunize chickens. Since chickens have neither trophoblasts nor trophoblast implantations and consequently have a totally different reproduction, which is based on the laying of fertilized eggs, they are capable of producing a sufficient immune response thereto. Then, the immune response can be immortalized as a phage library, for example, using the phage display technology. From these phage libraries, those single-chain antibodies are isolated which specifically bind to trophoblast cells. As an alternative or additional selection step, there may also be selected those single-chain antibodies which can



inhibit the syncytial fusion. The thus isolated antibody structures can in turn be used for isolating substances which mimic the structure of trophoblast epitopes. For example, substance libraries, such as peptide libraries, which may optionally also be present as phage display libraries, can be screened. Since the thus obtained peptides are "mimics" of the original epitopes, they may form the base for the development of vaccines which, after antibody production in the mammal, again have an inhibiting effect on the syncytial fusion and thus exhibit contraceptive activity.

In addition, the methods and compounds according to the invention can also be employed in tumor diagnostics and treatment. The above described transmigration of tissue by epithelial cells having detached from their basal membrane can be observed, apart from pregnancy, only in malignant tumors, especially in the carcinomas derived from epithelial and glandular tissues.

The invasion of malignant degenerate epithelial cells has its ontogenetic precursors in the invading trophoblast cell. Therefore, both invasive situations have similar properties:

a) Although malignant degenerate cells are genetically and phenotypically different from the normal body cells, there is no clinically effective immune response against these cells. Similarly, a human trophoblast is not rejected, although it is even an allohaploid transplant, formally. In both processes, the expected T-cell mediated immune response does not occur.

b) Many molecules which are expressed in the trophoblast during pregnancy do no longer appear in normal adult tissues. However, they may be reexpressed during malignant degeneration. Those epitopes which are expressed both during the fetal period and during carcinogenesis are designated as oncofetal epitopes. Due to the extended analogies between trophoblastic invasion and tumor invasion, there is a wide field of application for the immunological binding molecules according to the invention and the low molecular weight substance in the field of tumor diagnostics and tumor therapy.

Further epitopes which could be of particular value to the method according to the invention include:

- a) epitopes formed by oligomeric to polymeric carbohydrates, irrespective of whether they exist by themselves or occur in association with proteins, lipids or nucleic acids;
- b) epitopes formed by the association of subunits at the surface of cells, especially receptor molecules as well as virus-cell, cell-cell and cell-matrix contact molecules.

Figure 1 shows an agarose gel of the inserts of some members of a phage library. For checking the diversity of the cumulative library, 9 clones were arbitrarily picked, the plasmids were isolated and the inserts amplified in a PCR. The PCR products were purified, restricted with MspI, separated in a 2% agarose gel and stained with ethidium bromide. The sample rows are arranged as follows from left to right with ascending numbers. Row 1: 100 bp size ladder; row 2:  $\Phi$ X174/HaeIII; rows 3-11: clones 1-9. This shows that the library is not dominated by a few clones.

#### Example

The following embodiments are illustrative of the application of the method according to the invention. The example comprises the steps of immunization of a non-mammal with different antigen preparations, the establishing of a phage library, and the selection of specific immunological binding molecules as intended in the method.

#### *Immunization of the animals*

Twelve white leghorn chickens aged from 6 to 18 months were immunized. The immunization protocols were based on published standard schemes (Gassmann, M. et al., FASEB J. (1990) 4: 2528-2532) and comprised a first injection of the antigen preparation (see Table 2) in complete Freund's adjuvant, followed by two booster injections at intervals of 2 to 4 weeks each. The booster injections were

performed with incomplete Freund's adjuvant. When the immunization was effected with living human cells, a million cells was administered per injection with no adjuvant (see also Table 2). Five days after the last injection, the immunized animals were sacrificed, the spleens were removed and transferred to the laboratory in a sterile isotonic solution.

#### *Preparation of splenocytes, total RNA and cDNA*

Under sterile conditions, the spleen was cut into 8-10 smaller pieces. These pieces were further carefully suspended manually in 3 ml of sterile isotonic saline in an Elvehjem glass tube using the appropriate pestle. The resulting suspension was filtrated through a stainless steel sieve (150 mesh), the splenocytes contained in the filtrate were centrifuged to a pellet (400 x g, 5 min at room temperature), followed by selectively lysing the erythrocytes in lysis buffer (0.15 M  $\text{NH}_4\text{Cl}$ ; 1 mM  $\text{KHCO}_3$ ; 0.1 mM  $\text{Na}_2\text{EDTA}$ ; pH 7.2). From the remaining splenocytes, the total RNA was prepared, and cDNA was produced with oligo-dT primers after reverse transcription.

#### *Polymerase chain reactions (PCR) for establishing libraries*

Primers which can be used for amplifying the variable regions of the light (Vk) and heavy chains (Vh) of the immunoglobulin cDNAs are summarized in Table 1 (Andris-Widhopf, J., et al., J. Immunol. 2000 (in press)). The PCR was performed with the following parameters: The initial denaturation was effected at 94 °C for 1 min, followed by 30 cycles with 15 s of denaturation (94 °C), 15 s of annealing (56 °C) and 90 s of elongation (74 °C). The primers introduce an overlap region which is required for splice overlap extension PCR in the establishing of the segments coding for scFv. The PCR yields products with sizes of about 350 bp. After being thoroughly purified, the products were employed for splice overlap extension PCR.

### *Splice overlap extension PCR*

Equimolar amounts (100 ng each) of the amplicates of V<sub>k</sub> and V<sub>h</sub> were employed in splice overlap extension PCR. The reaction mixtures further contained a pair of specifically defined primers (see Table 1; Andris-Widhopf, J., et al., J. Immunol. 2000 (in press)) which introduce the restriction sites into the product, which are required, inter alia, for restriction and ligation. Initial denaturation at 94 °C for 1 min was followed by 35 cycles with 15 s of denaturation (94 °C), 15 s of annealing (56 °C) and 120 s of elongation (74 °C). The desired product has a size of about 750 bp.

### *Vector and ligation*

The vector used was pComb3H-SS (Barbas, C.F., 3rd. Curr. Opin. Biotechnol. (1993) 4: 526-530, Biassoni, R. et al., Semin. Cancer Biol. (1999) 9: 13-18, Siegel, D.L. et al., J. Immunol. Methods (1997) 206: 73-85, Andris-Widhopf, J., et al., J. Immunol. 2000 (in press)).

This vector and the above described primers were especially prepared and designed for the phage display of antibody libraries in the Scripps Research Institute, La Jolla, California, USA.

Prior to the ligation, the vector was linearized by digestion with SfiI. Since the vector contains two asymmetric cleaving sites of this restriction enzyme, directional cloning is directly possible after digestion and purification of the vector without an additional digestion step. At the same time, the product of the splice overlap extension PCR was also digested with the enzyme, and the restricted product was purified.

### *Establishing of the phage antibody libraries*

The prepared vector (14 µg) and the PCR product (10 µg) were incubated together in the presence of 20 units T4 ligase over night at 4 °C, the reaction products were precipitated with ethanol and resuspended in 50 µl of bidistilled water. This DNA

solution was used to transform electrocompetent *E. coli* (XL-1 Blue). The number of transformants was determined by titration on LB ampicillin plates (Sambrook, J., Fritsch, E.F. and Maniatis, T., Cold Spring Harbor Laboratory (1989), Cold Spring Harbor, NY), and the phage libraries were harvested after superinfection of the transformed *E. coli* with the helper phage M13KO7. The libraries in the phage form were stored both individually and as a mixed total library (cumulative library).

In order to get an impression of the diversity of the library and to exclude a dominance of just a few clones, the band patterns of 9 arbitrarily selected clones were analyzed after restriction of the insert (see Figure 1).

#### *Selection of specific phage antibodies from the cumulative library*

A combination of phosphatidylserine and beta-2-glycoprotein 1 (GP1) was chosen as the antigen for the selection. It is known that autoantibodies against this combinational epitope are associated with disorders of syncytial fusion. The autoantibodies are characterized by binding to phosphatidylserine, which appears at the outside of the cells shortly before fusion, in the presence of GP1.

To obtain antibodies having a specificity comparable to that, the following selection strategy was adopted:

- 1) 0.1 µg of phosphatidylserine was dissolved in 100 µl of ethanol and bound in an ELISA well at 37 °C.
- 2) The well was washed three times with bidistilled water for 5 min.
- 3) The well was incubated (30 minutes at 37 °C) with phosphate-buffered (pH 7.2) isotonic saline (containing 10% fetal calf serum). At the same time, the phages to be selected were also incubated with the same solution under the same conditions in a well containing no phosphatidylserine. The calf serum serves both as a blocking agent and as a source of GP1. Human and bovine GP1s are highly homologous proteins which are both recognized by the human autoantibodies.

4) The phage suspension was added to the well containing phosphatidylserine and incubated at 37 °C for 1 h.

5) After this incubation time, the phage-containing suspension was removed from the well and washed at least three times with phosphate-buffered (pH 7.2) isotonic saline (containing 10% fetal calf serum) for 5 min each to remove non-specifically binding phages and those phages which react with GP1 alone.

6) Binding phages were eluted with glycine buffer (pH 2.2), the solution was neutralized, and the phages obtained were used for infection of *E. coli* XL-1 Blue. After amplification of the eluted phages in *E. coli* over night, the phages produced were harvested and recycled to step 1. Steps 1 to 5 were thus performed a total of five times in succession. The stringency of the washing steps in step 5 was increased in every cycle by extending the washing time.

From the phage population recovered after the last cycle, 15 arbitrary clones were isolated, and monoclonal phage suspensions were prepared by culturing over night.

The isolated clones and the unselected phages of the cumulative library were tested for reactivity with phosphatidylserine in a phage ELISA.

Thus, steps 1 to 5 as described above were performed. Subsequently, the wells were incubated with a commercial mouse antibody against the phages and with a peroxidase-coupled antibody against mouse immunoglobulins. The peroxidase was detected by a chromogenic reaction, and the dye quantity was determined by photometry in an ELISA reader. A higher absorption indicates a higher number of binding phages. The results for 15 clones and the cumulative library are summarized in Table 3. Among the 15 clones, there are some (1, 2, 4, 8, 10 and 15) which bind very much more strongly to phosphatidylserine than the phages of the cumulative library do. This is demonstrated by the successful enrichment and selection of specifically binding antibodies from the cumulative library.

## Tables

**Table 1: Sequences of the primers for the amplification of Vh and Vk and the overlap extension PCR**

<b>Acronym</b>	<b>PCR: Vh and Vk</b>
<b>CSCVK</b> <b>CKJo-B</b>	<b>a) Vk</b> 5' GTGGCCCAGGCGGCCCTGACTCAGCCGTCCTCGGTGTC3' 5' CGAAGATCTAGAGGACTGACCTAGGACGGTCAGG3'
<b>CSVHo-F</b> <b>CSCG-B</b>	<b>b) Vh</b> 5' GGTCAGTCCTCTAGATCTTCCGCCGTGACGTTGGACGAG3' 5' CTGGCCGGCCTGGCCACTAGTGGAGGAGACGATGACTTCGGTCC3'
	<b>Overlap extension PCR</b>
<b>CSC-F</b> <b>CSC-B</b>	5' GAGGAGGAGGAGGAGGAGGTGGCCCAGGCGGCCGTGACTCAG3' 5' GAGGAGGAGGAGGAGGAGGAGCTGGCCGGCCTGGCCACTAGTGGAGG3'

**Table 2: Designation, antigen and size (number of transformants) per library**

<b>Phage display library (PDL)</b>	<b>Antigen</b>	<b>Transformants</b>
<b>PDL 1-4</b>	homogenizate of mature human placenta	$1.2 \cdot 10^9$
<b>PDL 5</b>	living cells, trophoblast cell line AC1-1	$10^7$
<b>PDL 6</b>	living cells, trophoblast cell line Jeg-3	$9.1 \cdot 10^7$
<b>PDL 7</b>	living cells, trophoblast cell line AC-1M88	$8.6 \cdot 10^7$
<b>PDL 8</b>	primary villous trophoblast, freshly isolated from a mature placenta	$1.8 \cdot 10^9$
<b>PDL 9</b>	primary invasive trophoblast, freshly isolated from fetal membranes of a mature placenta	$3.8 \cdot 10^7$
<b>PDL 10</b>	living cells, trophoblast cell line AC-1M32	$3.1 \cdot 10^7$
<b>PDL 11</b>	living cells, trophoblast cell line AC-1M59	$2.1 \cdot 10^7$
<b>PDL 12</b>	purified human beta-2-glycoprotein I	$2 \cdot 10^8$
<b>PDL 15</b>	homogenizate of rat placenta	$4.7 \cdot 10^7$
<b>PDL (cumulative library)</b>	mixture of all phage libraries	total: $4 \cdot 10^9$



**Table 3: Comparison of the 15 clones with the initial library in phage ELISA**

<b>Phage population</b>	<b>Number of phages applied per well</b>	<b>PHS-coated well (absorption)</b>	<b>Control well with no PHS (absorption)</b>
<b>Clone 1</b>	$10^9$	1.04	0.34
<b>Clone 2</b>	$10^9$	0.99	0.28
<b>Clone 3</b>	$10^9$	0.43	0.29
<b>Clone 4</b>	$10^9$	0.99	0.24
<b>Clone 5</b>	$10^9$	0.33	0.27
<b>Clone 6</b>	$10^9$	0.78	0.22
<b>Clone 7</b>	$10^9$	0.34	0.29
<b>Clone 8</b>	$10^9$	0.96	0.27
<b>Clone 9</b>	$10^9$	0.62	0.32
<b>Clone 10</b>	$10^9$	1.22	0.34
<b>Clone 11</b>	$10^9$	0.28	0.34
<b>Clone 12</b>	$10^9$	0.67	0.30
<b>Clone 13</b>	$10^9$	0.54	0.33
<b>Clone 14</b>	$10^9$	0.87	0.29
<b>Clone 15</b>	$10^9$	1.21	0.34
<b>Cumulative library</b>	$10^9$	0.31	0.26

PHS is the abbreviation of phosphatidylserine.

CLAIMS:

1. A method for the preparation of specific monoclonal immunological binding molecules having binding capacity to mammal epitopes, comprising the following steps:
  - a) isolation of structures containing said epitopes to obtain an epitope preparation;
  - b) immunization of non-mammals with the epitope preparation to obtain an immune response;
  - c) immortalization of the immune response to obtain a library of immunological binding molecules;
  - d) selection of the immunological binding molecules by means of the epitopes to obtain specific monoclonal immunological binding molecules.
2. The method according to claim 1, characterized in that said monoclonal immunological binding molecules are antibodies or antibody fragments, especially single-chain antibodies (scFv).
3. The method according to any of claims 1 or 2, characterized in that said epitopes are expressed on the surfaces of cells, especially of trophoblasts or tumor cells.
4. The method according to any of claims 1 to 3, characterized in that said epitopes are oncofetal epitopes or epitopes involved in the syncytial fusion of trophoblasts.
5. The method according to any of claims 1 to 3, characterized in that said mammal species is *Homo sapiens*.

6. A method for the identification of low molecular weight substances mimicking mammal epitopes, wherein the specific monoclonal immunological binding molecules obtained by the method according to claims 1 to 5 are used for identifying, in a library of low molecular weight substances, those having a high binding affinity.
7. The method according to claim 6, characterized in that said library of low molecular weight substances contains peptides.
8. The method according to any of claims 6 to 7, characterized in that said library of low molecular weight substances is a phage peptide library.
9. An immunological binding molecule obtainable by a method according to at least one of claims 1 to 5.
10. A diagnostic agent containing at least one immunological binding molecule according to claim 9.
11. A low molecular weight substance obtainable by a method according to at least one of claims 6 to 8.
12. The low molecular weight substance according to claim 11, characterized by being a peptide.
13. The low molecular weight substance according to claim 12, characterized in that said peptide comprises from 7 to 15 amino acids.
14. A medicament containing at least one low molecular weight substance according to any of claims 11 to 13.
15. Use of the low molecular weight substance according to any of claims 11 to 13 for the preparation of a vaccine for contraception or for the preparation of a vaccine for tumor treatment.

Abstract

A method for the preparation of specific monoclonal immunological binding molecules having binding capacity to mammal epitopes, comprising the following steps:

- a) isolation of structures containing said epitopes to obtain an epitope preparation;
- b) immunization of non-mammals with the epitope preparation to obtain an immune response;
- c) immortalization of the immune response to obtain a library of immunological binding molecules;
- d) selection of the immunological binding molecules by means of the epitopes to obtain specific monoclonal immunological binding molecules.

The specific monoclonal immunological binding molecules obtained can be used for identifying, in a library of low molecular weight substances, those having a high binding affinity, thus mimicking the epitopes of mammals.

BEST AVAILABLE COPY

1/1




Fig. 1